Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04593758
Title To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613 (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Rafael Pharmaceuticals Inc.
Age Groups: adult | child | senior
Covered Countries USA

No variant requirements are available.